Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol

Arthritis Clinical Trial

Official title:

A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral Ulodesine Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01265264
• Other study ID #: BCX4208-203
• Status: Completed
• Phase: Phase 2
• First received: December 20, 2010
• Last updated: October 28, 2013
• Start date: December 2010
• Est. completion date: February 2013

Study information

• Verified date: October 2013
• Source: BioCryst Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether ulodesine and allopurinol combined for 12 weeks are effective in treating gout in patients who are not adequately responding to allopurinol alone.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 279
• Est. completion date: February 2013
• Est. primary completion date: July 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 69 Years

Eligibility

Inclusion Criteria:

• Age = 18 to < 70 years

• Baseline sUA = 6.0 mg/dL after at least 2 weeks of treatment on a stable 300 mg dose of allopurinol

• Documented diagnosis of gout according to the American Rheumatism Association --Preliminary Criteria for the Diagnosis of Gout

• Be willing and able to take colchicine 0.6 mg per day or naproxen 220-250 mg twice daily as prophylaxis for gout flares and, if needed, a single daily dose of a proton pump inhibitor to prevent gastrointestinal discomfort

• Female participants must:

• Be sexually abstinent

• Be surgically sterile

• Be postmenopausal or on stable contraception

• Male participants must:

• Be sexually abstinent

• Be > 1 year post-vasectomy

• Using condoms with spermicide with partners meeting female requirements

Exclusion Criteria:

• Unable to tolerate 300 mg allopurinol

• Unable to tolerate both colchicine 0.6 mg per day and naproxen 220-250 mg twice daily

• Prior participation in a clinical study with BCX4208

• Gout flare during the Screening Period that is resolved for less than 2 weeks prior to first treatment with BCX4208 or placebo (exclusive of chronic synovitis/ arthritis)

• Unstable angina, symptomatic arrhythmia, signs or symptoms compatible with New York Heart Association Class III or Class IV heart failure, history of long QT syndrome, or QTc interval < 350 msec or > 475 msec

• Poorly controlled hypertension (SBP > 160 mmHg or DBP > 100 mmHG at Screening or Baseline)

• Moderate or severe renal impairment and/or calculated creatinine clearance of < 60 mL/min(Cockroft-Gault method)

• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values > 2.0 x ULN

• CD4+ cell counts by flow cytometry < 500 cells/mm3

• Hemoglobin < 10 g/dL or > 18 g/dL males or < 10 g/dL or > 17 g/dL females White blood cell count < 3.7 x 109/L or > 11 x 109/L

• Female subjects who are pregnant, breastfeeding, or planning a pregnancy within the next 4 months

• Positive serology for hepatitis B surface antigen or hepatitis C or HIV type 1

• Immunocompromised or on systemic immunosuppressive medications or antirheumatic drugs (including anakinra and adrenocorticotropic hormone)from Screening to Day 92

• Azathioprine or 6-mercaptopurine within 14 days of first dose of allopurinol Hydrochlorothiazide in doses > 50 mg per day from Screening to Day 92

• Use of herbal/dietary supplements Screening to Day 92

• Recipient of any live or attenuated vaccine within 6 weeks of Screening

• Uric acid-lowering drugs other than allopurinol from Screening to Day 92 Systemic corticosteroids within 4 weeks prior to Day 1 (this does not include pulmonary or nasal inhaler containing corticosteroids, ophthalmic corticosteroids, joint injections, or low potency topical steroids)

• Investigational drug within 30 days prior to signing the ICF for this study

• Clinically significant and relevant drug allergies

• Chronic or recurrent infections (= 3 infections at the same site within 12 months)

• Cancer within 12 months-Except non-melanomatous localized skin cancer or completely excised and cured carcinoma-in-situ of uterine cervix or subjects who were previously treated for prostate or breast cancer if they currently are stable and have not been on chemo therapy within the last year prior to screening.

• Alcohol or drug abuse within 12 months of signing the ICF, or current substance dependence or abuse

• Other medical conditions which, in the opinion of the PI, would jeopardize the safety of the study subject or impact the validity of the study results.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Arthritis
• Gout
• Hyperuricemia
• Joint Disease
• Joint Diseases

Intervention

Drug:
• ulodesine
Oral dose administered daily for 84 days.
• Placebo
Oral dose administered daily for 84 days.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
BioCryst Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the dose response of ulodesine when combined with Allopurinol on sUA.	Level of serum uric acid levels be measured at Day 85 to evaluate in subjects with Gout.	Day 85	Yes